LysaKare 25 g/25 g solution for infusion
*Company:
Novartis Ireland LimitedStatus:
UpdatedLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 30 April 2025
File name
LysaKare_REG PIL_PF25-0085_27.03.2025_clean_IPHA.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 30 April 2025
File name
LysaKare_REG SPC_PF25-0063 and PF25-0085_27.03.2025_clean_IPHA.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to restricted prescription (C)
Updated on 03 May 2024
File name
LysaKare_25-25g REG PIL_PF24-0052_April2024_IPHA.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 4 - how to report a side effect
Updated on 02 May 2024
File name
LysaKare_REG SPC_PF24-0052_25-25g-g_April 2024_clean_IPHA.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
Legal category:Product subject to restricted prescription (C)
Updated on 20 September 2023
File name
LysaKare_25-25g_REG PIL_PF23-0151_19.09.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
Free text change information supplied by the pharmaceutical company
Update to local representative of MAH
Updated on 20 September 2023
File name
LysaKare_25-25g_REG PIL_PF23-0151_19.09.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
Free text change information supplied by the pharmaceutical company
Update to local representative of MAH
Updated on 21 March 2023
File name
LysaKare_25-25g-g_REGPIL_PF23-0042__13.02.2023_clean_IPHA_1.pdf
Reasons for updating
- Correction of spelling/typing errors
Updated on 21 February 2023
File name
LysaKare_25g-25g-REG SPC_PF23-0042_13.02.2023_clean_IPHA.pdf
Reasons for updating
- Change to MA holder contact details
Legal category:Product subject to restricted prescription (C)
Updated on 21 February 2023
File name
LysaKare_25-25g-g_REGPIL_PF23-0042__13.02.2023_clean_IPHA.pdf
Reasons for updating
- Change to MA holder contact details
Updated on 16 November 2021
File name
LysaKare_25g-25g-REG SPC_PF21-0170_Oct 2021_Clean_corr.pdf
Reasons for updating
- Correction of spelling/typing errors
Legal category:Product subject to restricted prescription (C)
Updated on 27 October 2021
File name
LysaKare_25-25g-g_PROPIL_PF21-0170__Oct 21_clean.pdf
Reasons for updating
- Change to MA holder contact details
Updated on 27 October 2021
File name
LysaKare_25g-25g-REG SPC_PF21-0170_Oct 2021_Clean.pdf
Reasons for updating
- Other
Legal category:Product subject to restricted prescription (C)
Updated on 19 October 2021
File name
LysaKare_25-25g-g_REG SPC_25-Jul-19_IPHA.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 19 October 2021
File name
LysaKare_25-25g-g_REG PIL_25-Jul-19_IPHA.pdf
Reasons for updating
- New PIL for new product
Novartis Ireland Limited
Address:
Vista Building, Elm Park Business Park, Merrion Road, Dublin 4, IrelandMedical Information E-mail:
medinfo.dublin@novartis.comTelephone:
+353 1 2601255Fax:
+353 1 2601263